We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

27 hedge funds and large institutions have $5.8M invested in Theriva Biologics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

722% more capital invested

Capital invested by funds: $705K → $5.8M (+$5.09M)

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

59% more funds holding

Funds holding: 17 → 27 (+10)

0.01% less ownership

Funds ownership: 0.04% → 0.03% (-0.01%)

Holders
27
Holders Change
+10
Holders Change %
+58.82%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
8
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.83M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.56M
3
MP
MSD Partners
New York
+$759K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$666K
5
UBS Group
UBS Group
Switzerland
+$456K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$474K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$28K
3
TRCT
Tower Research Capital (TRC)
New York
-$11.7K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.6M +$1.83M +9,240 +6,039%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.37M +$1.56M +7,913 +5,420%
MP
3
MSD Partners
New York
$655K +$759K +3,843 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$586K +$666K +3,371 +4,748%
UBS Group
5
UBS Group
Switzerland
$393K +$456K +2,308 New
Citadel Advisors
6
Citadel Advisors
Florida
$368K +$426K +2,156 New
VF
7
Virtu Financial
New York
$318K +$286K +1,449 +347%
Northern Trust
8
Northern Trust
Illinois
$168K +$184K +931 +1,693%
Fisher Asset Management
9
Fisher Asset Management
Washington
$87K +$1.58K +8 +2%
BCM
10
Bridgeway Capital Management
Texas
$75K – – –
William Blair & Company
11
William Blair & Company
Illinois
$48K +$12.8K +65 +30%
Charles Schwab
12
Charles Schwab
California
$36K +$41.3K +209 New
TI
13
tru Independence
Oregon
$30K +$47.4K +240 New
Victory Capital Management
14
Victory Capital Management
Texas
$14K +$16.4K +83 New
JCM
15
Jacobi Capital Management
Pennsylvania
$13K +$14.6K +74 New
NA
16
NewEdge Advisors
Louisiana
$10K +$11.3K +57 New
Creative Planning
17
Creative Planning
Kansas
$8K +$8.89K +45 New
SWP
18
Stratos Wealth Partners
Ohio
$7K +$8.5K +43 New
IA
19
IFP Advisors
Florida
$3K – – –
Wells Fargo
20
Wells Fargo
California
$1K +$395 +2 +200%
CWP
21
Concord Wealth Partners
Virginia
$1K +$790 +4 New
SPIA
22
Steward Partners Investment Advisory
New York
$98 – – –
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$1 – – –
Renaissance Technologies
24
Renaissance Technologies
New York
– -$474K -4,951 Closed
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
– -$28K -291 Closed
1
2

TOVX Hedge Fund Activity: Q1 2021 in Review

27 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2021, worth a combined $5.8M — up 722% from $705K a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new TOVX positions and 4 closed out — a net gain of 10 holders — while 8 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, adding an estimated $1.83M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $474K sold.

  • 27 institutional investors held Theriva Biologics (TOVX) as of Q1 2021, up from 17 in Q4 2020.
  • Funds reported $5.8M of Theriva Biologics stock for Q1 2021, up 722% quarter-over-quarter.
  • 14 funds opened new Theriva Biologics positions in Q1 2021 and 4 closed out, a net change of +10 holders.
  • The largest Theriva Biologics buyer in Q1 2021 was BlackRock, an estimated $1.83M added.
  • The largest Theriva Biologics seller in Q1 2021 was Renaissance Technologies, an estimated $474K sold.

Based on aggregated 13F filings for Q1 2021.